DJIA 17,619.51 23.16 0.13%
NASDAQ 4,986.87 28.40 0.57%
S&P 500 2,063.11 5.47 0.27%
market minute promo

MannKind Corp (NASDAQ: MNKD)

company name or ticker

Could Incoming Threats Sink MannKind Corporation?

Big Pharma suspected that MannKind's Afrezza would make its way to the market eventually. Now that its here, what does the industry have in its pipeline that could potentially slow adoption?

Interesting MNKD Put And Call Options For July 2nd

MannKind, Front and Center: The Best Product Doesn’t Always Equal the Best Stock

The Motley Fool's own Michael Douglass and Todd Campbell dig into MannKind Corp.'s first quarter earnings to see if MannKind is a bargain, or a bust.

MannKind's Afrezza Inhaled Insulin: A Game Changer For Seniors With Diabetes

Has MannKind Stock Finally Bottomed Out?

My Primary Care Provider's Take On Afrezza

MannKind Corporation: Afrezza Is Better Than Weak Launch Suggests

Wall Street Analysts Sell The Bottom In MannKind

MannKind (MNKD) in Focus: Stock Rises 10.1% in Session - Tale of the Tape

Forget MannKind Stock's Price: Here's What You Need to Focus on Instead

Is MannKind's small share price tempting you to buy? Use this simple mental test to evaluate your decision.
See More Articles...